Introduction {#S1}
============

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly ([@B2]). The pathological hallmarks of AD are the presence of extracellular plaques composed of amyloid-beta (Aβ) and intracellular neurofibrillary tangles composed of the microtubule binding protein tau in the brain ([@B10]; [@B16]). According to the amyloid cascade hypothesis, Aβ accumulation leads to tau deposition, triggers neuronal dysfunction and results in neuronal death ([@B47]; [@B109]). Although, amyloid cascade hypothesis is widely debated, soluble Aβ and tau protein aggregations have been shown to lead to synaptic dysfunction and loss of synaptic density ([@B113]), resulting in memory and cognitive deficits in AD patients ([@B31]). The clinical features of AD include progressive memory loss, impaired judgment and decision-making ([@B38]). Current therapeutics are limited to alleviation of symptoms, not reversing or slowing the disease progression ([@B142]; [@B29]). Therefore, there is an urgent need to identify effective treatment strategies for alleviating the disease burden.

In addition to memory and cognitive impairments, Alzheimer's patients experience sleep disruptions ([@B9]; [@B77]; [@B83]), leading to reductions of non-rapid eye movement (NREM) sleep and slow wave activity (SWA), a brain rhythm prevalent during NREM sleep ([@B93]). These disruptions include increased amounts and frequencies of nighttime wakefulness as well as daytime napping ([@B132]; [@B77]). Sleep disturbances manifest early since individuals with mild cognitive impairment (MCI), a pre-clinical stage of AD, suffer from sleep disruptions ([@B132]; [@B136]). Similarly, individuals with detectable amyloid beta, but cognitively healthy also suffer from sleep disturbances, defined as lower sleep quality and increased number of day-time naps ([@B56]). Thus, sleep and memory disruptions manifest early in the disease progression, prior to symptom onset.

Sleep mediates several forms of memory consolidation ([@B32]; [@B11]; [@B94]). Sleep disturbances are correlated with deteriorated memory function and cognitive decline in AD and MCI patients ([@B80]; [@B13]). Increased night-time wakefulness and decreased slow wave sleep (SWS), which is dominated by SWA, was associated with impaired memory and cognitive functions ([@B80]). NREM, in particular SWS, plays an important role in declarative memory consolidation ([@B134]; [@B68]). This review will provide an overview of the SWA disruptions in AD. It will also summarize the evidence for the causal relationship between AD pathology, Aβ/tau, and sleep-dependent memory consolidation deficits that are driven by the SWA disturbances in AD patients and animal models of AD. Furthermore, we will propose possible mechanisms underlying the SWA disruptions. Finally, we will discuss therapeutic strategies for targeting SWS in AD aimed at slowing the disease progression and restoring the sleep-dependent memory consolidation. This review is focused on the SWA, the most prominent neocortical activity with the increased power density in 0.5--4.0 Hz frequency range occurring during NREM sleep. It will not cover other NREM sleep-associated rhythms, such as thalamo-cortical sleep spindles, or hippocampal ripples, nor will it discuss REM sleep disruptions in AD, that have been reviewed or described elsewhere ([@B23]; [@B95]; [@B90]).

SWA and Sleep-Dependent Memory Consolidation {#S2}
============================================

Sleep consists of rapid eye movement (REM) and NREM sleep. REM sleep is characterized by desynchronized EEG activity with faster oscillations and lower voltage waveforms ([@B17]). Human NREM sleep is subdivided into stages N1--N3 (previously stages 1--4) and is defined by the electroencephalogram (EEG) activity as synchronous waveforms, including sleep spindles (12--14 Hz), K-complexes in stage 2 as well as slow (\<1 Hz) and delta (1--4 Hz) activity in stage 3 ([@B53]). Slow and delta oscillations or isolated slow waves are commonly called SWA ([@B126]). Stage N3, also referred to as Delta Sleep or SWS, is characterized by the high amounts of SWA ([@B17]).

Slow oscillation is a major rhythm of deep sleep. During slow oscillations, excitatory and inhibitory neocortical neurons from all layers (unknown for layer 1) in anesthetized ([@B114],[@B115],[@B116]) and sleeping animals ([@B124], [@B125]; [@B118]; [@B21]) oscillate between depolarized (active or UP) and hyperpolarized (silent or DOWN) states. Despite involvement of the entire thalamocortical system ([@B114]; [@B27]; [@B110]), the slow oscillations originate in neocortex as can be recorded in neocortical slices ([@B103]; [@B102]), cortical cell cultures ([@B119]; [@B50]) and isolated cortical slabs maintained *in vivo* ([@B123]; [@B65]). Slow oscillation is absent from the thalamus of decorticated animals ([@B127]). The silent (hyperpolarized or DOWN) states of slow oscillations are periods of disfacilitation, i.e., absence of synaptic activity. Leak currents primary mediate silent states ([@B122], [@B125]). The active (depolarized or up) states are mediated by barrages of excitatory and inhibitory synaptic activities at the level of soma ([@B118]; [@B125]; [@B101]) and major Ca^2+^ activities in dendrites ([@B78]; [@B107]). Neocortex generates slow oscillations while thalamus contributes to their maintenance as thalamic inactivation temporally modifies cortical SWA ([@B30]; [@B65]).

To control the slow oscillations, it is important to understand the major cellular events taking place during SWA. The neuronal firing and thus synaptic activity in local cortical networks, is essentially absent in the silent state. Two major mechanisms for the active state onset are proposed. (i) The silent state is partially mediated by Ca^2+^- and Na^+^-dependent K^+^ currents. A reduction in these currents leads to the onset of a new active state ([@B103]). (ii) Silent states are characterized by the absence of synaptic activity, but spike-independent neurotransmitter release (miniature postsynaptic potentials, minis) are still present. Co-occurrence of minis in large neurons that possess a high number of postsynaptic sites can lead to significant depolarizations and initiations of spikes, that would drive the whole network into an active state ([@B123]; [@B7]; [@B21]). Since this is a stochastic process, it can start in any cell, but more often, it starts in larger neurons, typically layer 5 large cortical pyramidal cells in experimental animals ([@B21]; [@B37]). In human, however, slow wave active states more often start in layer 3 ([@B18]; [@B28]). There might be two reasons for this difference: (a) human pyramidal cells from layer 3 are very large ([@B82]), and therefore, they are well situated to summate minis and to trigger active states; and (b) enhanced electrical compartmentalization in layer 5 pyramidal neurons in humans does not allow dendritic depolarizing events to reach soma, even in the presence of dendritic spikes ([@B8]), therefore reducing overall implication of layer 5 cells in network operation. Local origin of active states and dense synaptic interactions in the cortex trigger propagation of slow waves across cortical mantle ([@B76]; [@B133]; [@B110]). Active states are mediated by interactions of excitatory and inhibitory conductances ([@B44]; [@B46]; [@B22]) with overall stronger inhibition at the level of soma ([@B101]; [@B45]). A termination of active states and transition to silent states occurs due to several factors: (i) activation of Na^+^- and Ca^2+^-dependent potassium currents ([@B103]), (ii) synaptic depression ([@B124]), and (iii) synchronous active inhibitory drive ([@B115]; [@B64]). Because active states terminate nearly simultaneously across large cortical territories ([@B133]; [@B110]), intrinsic current activation or synaptic depression likely do not play a leading role, because they are cell specific. Thus, we suggest that active inhibitory mechanisms terminate active states and provide network-wide synchronous onset of silent states. First, somatostatin-positive GABAergic interneurons increase activity prior to the onset of silent states ([@B39]; [@B87]). Most of these interneurons have short axons, therefore an external trigger, possibly from thalamus, synchronizes them. Indeed, thalamic inactivation abolishes synchronous onset of silent states ([@B64]). Furthermore, some thalamocortical neurons fire during silent states driving parvalbumin-positive interneurons ([@B144]). Another potential source is claustrum, the structure that has widespread cortical projections and, if activated optogenetically, induces cortical down states ([@B84]). It appears that claustrum is well situated to drive simultaneously cortical interneurons across different areas just prior to the onset of silent states.

Sleep slow oscillations play an important role in cortical plasticity. However, the direction of these plastic changes is still under discussion. A subset of studies, based mainly on indirect measurements, propose that cortical synaptic connections are strengthened during wakefulness and are weakened during sleep ([@B128], [@B129]). Other studies demonstrate that slow oscillations and overall sleep strengthens efficacy of cortical synapses ([@B4]; [@B20]; [@B105]; [@B141]; [@B55]; [@B121]). Finally, there is an attempt to reach agreement in this debate which proposes that some synapses are upregulated and others are downregulated by sleep ([@B106]).

Irrespective of the synaptic mechanisms, slow oscillations play an important role in sleep-dependent declarative memory consolidation ([@B117]; [@B73]; [@B134]; [@B68]). Born and colleagues proposed a model of declarative, hippocampus-related memory consolidation during SWS. Cortical slow oscillations drive the reactivation of short-term hippocampal memories by synchronizing hippocampal sharp wave ripples with spindle activity in the thalamus during slow oscillation UP states. This mechanism thereby contributes to the long-term synaptic plasticity changes in neocortical networks and supports the consolidation of long-term memory in neocortex ([@B32]; [@B94]). SWS declines with increasing age especially after the age of 30 ([@B130]). Age-related reduction in SWS was correlated with impaired sleep-associated memory consolidation ([@B5]). Furthermore, insomnia patients with less SWS showed declines in overnight declarative memory consolidation compared to age-matched controls ([@B6]). Boosting SWA facilitated sleep-dependent memory consolidation ([@B73]). Thus, SWA, slow oscillations in particular, is necessary and sufficient for memory consolidation during sleep, and we propose that SWA disruptions might contribute to memory impairments in AD.

SWA Disruptions in AD Patients {#S3}
==============================

Toxic Aβ is thought to initiate pathological events and drive the formation of pathological tau aggregates that ultimately lead to synaptic loss and cell death ([@B47]; [@B109]; [@B48]), which in turn compromises neuronal circuitry. Aβ levels correlate with sleep alterations in cognitively normal individuals with preclinical AD ([@B56]; [@B112]). Neuronal activity disturbances including slow oscillation disruptions were reported in older adults ([@B72], [@B71]; [@B70]). Aβ and tau deposits were associated with decreased NREM SWA in cognitively normal older adults and in early stages of AD ([@B71]; [@B70]). Decreased NREM slow oscillations (0.6--1 Hz) were associated with increased Aβ accumulation in the medial prefrontal cortex ([@B71]). Also, higher tau deposition was correlated with decreased delta power (1--4 Hz) ([@B70]). This evidence provides strong support for a relationship between SWA disruptions and AD pathology ([Figure 1](#F1){ref-type="fig"}). In addition to SWA disruptions in asymptomatic cognitively normal adults, SWA was reduced in MCI individuals ([@B136]). Sleep disturbances in cognitively normal older adults could predict the Aβ burden and tau accumulation later in life ([@B137]). Taking into account all of the above, we propose that, sleep-wake cycle disturbances, especially decreases in NREM SWA, may serve as a potential early biomarker for AD.

![Schematic representation of the causal relationship between NREM SWS, memory consolidation, and AD pathology. Low NREM SWS leads to reduced SWA and perivascular clearance of soluble Aβ and is associated with impaired memory consolidation. Further, low SWA is associated with increased Aβ/tau aggregation in AD patients. Ways to restore NREM SWA are proposed for animal models and Alzheimer's patients, where these might lead to a promising therapeutic strategy for AD. Abbreviations: NREM SWS, non-rapid eye movement slow wave sleep; SWA, slow wave activity; Aβ, amyloid-beta; AD, Alzheimer's disease; tDCS, transcranial direct current stimulation; TMS, transcranial magnetic stimulation.](fnins-14-00705-g001){#F1}

Aberrations in SWA correlated with disrupted memory consolidation in MCI patients ([@B136]) and older adults ([@B71]). Therefore, it stands to reason that slow oscillation disruptions in individuals with early AD might contribute to and accelerate the progressive memory and cognitive decline. In turn, AD pathology might further disrupt sleep-dependent brain rhythm activity that further exacerbates AD ([Figure 1](#F1){ref-type="fig"}).

Glymphatic system hypothesis, although still debated ([@B1]), states that soluble Aβ is cleared along perivascular pathways, including through the glymphatic system ([@B54]). SWS enhanced the clearance of Aβ when compared to the waking state ([@B139]). Interestingly, soluble Aβ levels fluctuated with the sleep-wake cycle in humans. Aβ levels were elevated during waking and declined during sleep ([@B57]; [@B69]), suggesting that sleep facilitates Aβ clearance. Thus, there is accumulating evidence for a relationship between Aβ, sleep and neuronal activity disruptions ([Figure 1](#F1){ref-type="fig"}).

SWA Disruptions in Mouse Models of AD {#S4}
=====================================

Mouse models of AD provide a powerful means to study SWA disruptions. Amyloidosis models recapitulate Aβ production, amyloid plaque deposition and associated neuropathology exhibited by Alzheimer's patients. Tauopathy models mimic tau production, intracellular tau tangles and associated neuropathology. Furthermore, slow oscillation disruptions were recapitulated in mouse models of amyloidosis and tauopathy ([@B51]; [@B59]; [@B19]). Wide field imaging using voltage sensitive dyes (VSD) and genetically encoded reporters, in addition to traditional methods, such as electrophysiology, allowed monitoring SWA in mice. Similar to those in humans ([@B76]), slow oscillations propagate across cortex in mice as traveling waves between two hemispheres ([@B81]). We used a transgenic mouse model of amyloidosis (APPswe/PS1dE9 mice; APP mice) to show that the cortical slow wave power but not the frequency was decreased in young ([@B59]) and older mice ([@B58]). APP mice spent less time in NREM sleep ([@B99]). Tg2576 mice exhibited decreases in SWA; and their power spectral density was shifted to higher frequencies ([@B61]). As for tauopathy models, P301S human tau transgenic mice exhibited sleep-wake cycle disruptions, reductions in NREM sleep and increased wakefulness. Moreover, their SWA was significantly decreased during NREM sleep ([@B51]). Furthermore, the transgenic mouse model 3xTg-AD, which develops plaque and tangle pathology, exhibited slow waves at lower frequency and reduced firing rate ([@B19]). Thus, these animal models recapitulated SWA disruptions exhibited by Alzheimer's patients ([@B70]). It should be noted that animal models do not recapitulate all aspects of human condition. Mice have more primitive cortex and hence slow oscillations present in mice are not as complex as those recorded in humans. During aging, sleep in mice undergoes changes, sometimes dissimilar to those in humans. For example, aged mice exhibit less SWS compared to young mice. The power of slow-wave activity in aging mice is increased when measured in frontal cortex, while slow wave power in aging human adults is decreased. On the other hand, aging mice also exhibit similarities to aging humans. For example, aged mice exhibit increases in sleep fragmentation, increases in sleep duration during active phase of sleep-wake cycle (light for humans, dark for mice), and decreased REM sleep at the end of quiet phase of sleep-wake cycle ([@B111]). Thus use of mouse models should be considered with caution when modeling human condition. Despite these limitations, the mouse models were successfully used to monitor and modulate activity of specific neuronal and non-neuronal populations that contribute to the disruptions of slow waves (see below). Uncovering the neural circuit mechanisms that underlie the SWA disruptions could lead to the discovery of novel therapeutic strategies.

Mechanisms Underlying SWA Disruptions in AD {#S5}
===========================================

Observations from human studies demonstrated that disrupted SWA contributed to the impairments of memory consolidation in AD patients. However, the mechanisms that underlie SWA disruptions remain largely unknown. Aβ peptides target synapses and disrupt excitatory and inhibitory neurotransmission leading to neural network dysfunction ([@B108]). This indicates that, SWA anomalies in aMCI and AD patients might be due to the neuronal network dysfunction resulting from neuronal hyper- and hypoactivity. Animal studies using multiphoton microscopy elucidated deficits in inhibitory tone as one possible mechanism for disrupted SWA ([@B14]; [@B59]). Deficits in synaptic inhibition led to neuronal hyperactivity ([@B14]) and caused desynchronized circuit activity within cortical excitatory neurons ([@B59]). More than 20% of the layer 2/3 cortical neurons exhibited hyperactivity surrounding Aβ plaques. This hyperactivity was reduced when hyperactive neurons were treated with the gamma-aminobutyric acid A (GABA~A~) agonist diazepam ([@B14]), while slow oscillations were rescued by topical application of GABA directly onto the somatosensory cortex ([@B59]). In addition to low GABA levels, the expression of GABA~A~ and GABA~B~ receptors was downregulated in APP mice ([@B59]). Interestingly, application of either GABA~A~ or GABA~B~ inhibitors disrupted slow oscillations in healthy wild-type animals, mimicking slow wave disruptions in APP mice ([@B59]). As we indicated earlier, GABAergic neurons play a critical role in the onset of cortical silent states, the major element of SWA. Topical applications of a GABA~A~ receptor agonist rescued slow waves and sleep-dependent memory consolidation in transgenic mice ([@B15]). Thus, APP mice exhibit cortical hyper- and hypoactivity due to deficits in inhibitory elements of the circuit, specifically GABA, GABA~A~, and GABA~B~ receptors, the activity of which is necessary and sufficient for normal SWA.

Alzheimer's disease is a truly progressive disorder. Deficits in inhibitory elements of the circuit were followed by deficits in excitatory elements ([@B58]). The protein levels of the cortical excitatory neurotransmitter glutamate were examined in APP mice. Glutamate levels were comparable in APP and wild-type littermates at 7 months of age ([@B59]). However, by 9 months of age, APP mice started showing deficits in glutamate levels ([@B58]). These findings indicate that the disturbances of synaptic inhibition followed by a deficiency in synaptic excitation within the neuronal circuits may be related to the disruptions of slow oscillations in AD. Furthermore, administration of the glutamate receptor antagonists alleviated hyperactivity in APP mice ([@B14]). Taken together, inhibition deficits followed by excitation deficits within the slow wave circuits most likely contributed to the disruption of slow oscillations early in the disease progression and impaired sleep-dependent memory formation.

In addition to inhibitory and excitatory neurons, cortico-thalamic circuits rely on astrocytes to maintain their normal function ([@B3]; [@B91], [@B92]). Astrocytes are the glial cells that maintain glutamate and GABA recycling via glutamate/GABA-glutamine cycles. Astrocytes form the tripartite synapses with pre- and post-synaptic neuronal compartments to regulate synaptic transmission via astrocytic calcium signaling ([@B3]; [@B85]). Astrocytic contributions to normal circuit function has been underappreciated until recently ([@B26]; [@B60]). Amyloid deposits disrupted astrocytic topology ([@B40]), and astrocytic calcium dynamics were altered in APP mice ([@B62]). Furthermore, elevations in resting calcium concentrations were reported in astrocytes in APP mice ([@B62]). Thus, aberrant astrocytic activity might contribute to the SWA disruptions in AD. Furthermore, the protein expression levels of glutamate transporters GLAST and GLT-1, which localize specifically to astrocytic plasma membrane, were decreased in the cortex and hippocampus in a mouse model of AD ([@B104]). Alterations in astrocytic elements of the circuit were also reported in brain tissue from AD patients. The expression of astrocytic glutamine synthetase was decreased in close proximity to Aβ plaques in AD brains ([@B98]). Interestingly, aberrant expression of glutamine synthetase was detected in a subpopulation of pyramidal neurons in AD individuals ([@B98]), suggesting that the glutamate-glutamine cycle was disrupted. The abnormalities in astrocytic activity may contribute to aberrant neuronal firing and lead to the disruption of neuronal networks, thus perturbing SWA. Indeed, astrocytes participated in triggering slow oscillation UP states *in vitro* ([@B91]) and *in vivo* ([@B92]; [@B120]). [@B92] visualized intracellular calcium transients and demonstrated that astrocytes had modulated extracellular glutamate, thus triggering the SWA in mouse brains. Furthermore, [@B120] showed that blocking astrocytic calcium transients resulted in reduced numbers of astrocytes and neurons participating in the SWA. This series of studies supports the idea that astrocytes are necessary and play a critical role in induction of slow oscillation UP states in the cortical circuits. Therefore, astrocytic network studies using animal models are important to understand the role of astrocytes in slow wave dysfunction in AD. Finally, understanding the role of astrocytes in SWA disruptions might point to a novel therapeutic strategy for Alzheimer's patients.

Optogenetic Control of Slow Oscillations in Mouse Models of AD {#S6}
==============================================================

Optogenetics is a leading-edge research tool that can be used to gain valuable insight into the causal relationship between circuit dynamics and Alzheimer's progression using animal models ([@B12]; [@B67]). This methodology provides high spatiotemporal precision with cell-type specificity. Distinct cell types can be targeted *in vivo* using cell-type specific promoters with light-activatable channels or proton pumps ([@B36]). Light activation of cells expressing the channels or pumps can be used to manipulate the activity within neural circuits of interest. Optogenetics has been successfully adopted to studies of AD using mouse models.

Optogenetics was used to increase neuronal activity chronically in hippocampal perforant pathway in AD mice. This exacerbated hyperactivity in the circuit and increased interstitial fluid Aβ42 levels as well as Aβ deposition in the projection areas ([@B140]). Optogenetic-mediated increases in neuronal activity also elevated release and propagation of tau in htau mice ([@B138]). This evidence further solidified the fact that aberrant synaptic activity facilitated AD progression ([@B25], [@B24]). Optogenetics was also used to shed light onto the state of brain rhythms in AD. Optogenetic entrainment of interneurons in the gamma frequency range restored gamma oscillations and reduced Aβ deposition in a mouse model of AD ([@B52]). Our laboratory reported that light-activation of channelrhodopsin-2 (ChR2)-expressing excitatory neurons at the endogenous frequency of slow waves in APP mice for 4 weeks rescued aberrant slow oscillations by restoring slow wave power. It also restored GABA as well as GABA~A~ and GABA~B~ receptor levels ([@B59]). In addition, chronic restoration of SWA halted Aβ plaque deposition and prevented intraneuronal calcium elevations (defined as calcium overload) ([@B59]). Alternatively, driving slow waves at twice the endogenous frequency using optogenetics augmented Aβ production, increased neuronal calcium overload and decreased the synaptic spine density ([@B58]). Optogenetic restoration of circuit activity slowed pathology progression in mouse models of AD, while optogenetic increases in the frequency of slow waves accelerated the progressive pathophysiology and resulted in neuronal network failure.

Similarly, modulations of brain wave activity restored memory deficits in experimental models using optogenetics. Synchronization of SWA in somatosensory and motor cortices using optogenetics was able to restore perceptual memory impairment and prolong memory retention in sleep-deprived mice ([@B79]). In addition, restoration of hippocampal oscillations with optogenetics resulted in an improvement of recognition memory in APP mice ([@B43]). Also, optogenetic activation of memory engram cells in hippocampus increased spine density in engram cells and restored long-term memory ([@B100]). Furthermore, gamma oscillation rescue using optogenetics improved spatial memory in an AD mouse model ([@B35]). Restoring brain oscillations by optogenetic approaches in mouse models provides insight into novel therapeutic approaches to treat and/or prevent AD altogether. Animal studies suggest that restoring brain oscillation activity, including SWA, may be an effective therapeutic strategy for reducing memory deficits in AD patients.

Restoring Slow Wave Sleep Is a Promising Therapy for AD {#S7}
=======================================================

Currently, there are no effective treatments able to slow AD progression and alleviate cognitive and memory impairments in patients. The majority of clinical therapeutic approaches focus on clearing Aβ and tau with monoclonal antibodies using passive immunotherapies ([@B131]). Light therapy had mixed results in the clinic ([@B34], [@B33]; [@B97]). However, a large number of clinical trial failures underscores the need to identify novel therapeutic strategies for treating AD.

Restoration of SWA during NREM sleep in Alzheimer's patients might slow the disease progression and rescue sleep-dependent memory consolidation. Transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) are two noninvasive brain stimulation methodologies that could potentially be used to do so. Recently, tDCS was applied to human MCI subjects during daytime nap to investigate the patterns of SWA and sleep-dependent memory consolidation. Both the slow oscillation power and memory performance were improved after stimulating the brain at the slow oscillation frequency with tDCS ([@B63]). Furthermore, repeated applications of tDCS induced slow oscillations during SWS and led to enhanced declarative memory retention the next day in older ([@B135]) and in young healthy adults ([@B74], [@B73]). In a similar study, TMS was used to evoke slow waves during NREM sleep. TMS increased SWA power in healthy young subjects ([@B75]). In addition to tDCS and TMS methodologies, slow oscillations can be enhanced with auditory stimulation ([@B86]; [@B66]; [@B89]; [@B88]). Applied auditory tones that were phase-locked to the up states of slow oscillations during sleep benefited declarative memory consolidation in healthy young adults ([@B86]; [@B66]) and in older subjects ([@B89]). Furthermore, phase-locked acoustic stimulation also enhanced memory encoding during nap in healthy young subjects ([@B88]). Another sensory stimulation strategy visual stimulation, can be used to induce SWA ([@B96]). Using high-density EEG recordings in healthy young subjects during NREM sleep, SWA was successfully evoked by visual stimuli ([@B96]). Thus, tDCS, TMS, acoustic, and visual stimulations could potentially be used to enhance sleep-dependent memory consolidation in healthy subjects and AD patients in early stages of the disease.

Targeting specific GABAergic neuronal circuit elements may be particularly attractive in designing new AD therapies. Whereas restoration of parvalbumin interneuron activity acutely restored gamma oscillations ([@B52]) and prevented memory loss as well as network hyperexcitability ([@B49]), activation of either neuronal nitric oxide synthase (nNOS) or somatostatin neurons may be useful for restoring SWA. A recent study involving the chemogenetic activation of SST-positive cells in the cerebral cortex showed increased SWA, elevated slope of individual slow waves, and prolonged NREM sleep duration compared to control conditions. Alternatively, chemogenetic inhibition of these cells reduced SWA and slow-wave incidence without changing time spent in NREM sleep ([@B39]). We previously demonstrated that nNOS neurons are activated during episodes of NREM sleep associated with increased SWA ([@B42]). We also showed that optogenetically evoked responses in nNOS-positive cells of the cerebral cortex are consistent with their role in slow-wave sleep physiology ([@B41]). Furthermore, mice lacking nNOS expression in SST positive neurons exhibited significant impairments in both homeostatic low delta frequency range SWA production and a recognition memory task that relies on cortical input ([@B143]). Further studies will determine whether activation of nNOS/somatostatin neurons in the cerebral cortex is efficient in reducing AD pathology, and whether this effect is mediated by SWA enhancement. Finally, instead of activating endogenous interneurons, it would be promising to explore cell-based therapeutic strategies, such as transplantation of human stem cell-derived interneurons to increase inhibitory tone and restore SWA.

Discussion {#S8}
==========

In addition to memory disruptions, Alzheimer's patients experience disturbances in their sleep-wake cycles, due to increased nighttime wakefulness and decreased NREM SWS. AD pathology is correlated with SWA disruptions at the early stages of AD. Decreased SWA was found in asymptomatic cognitively normal adults and aMCI patients. Since slow oscillation disruption is an early event, it has the potential to be used as an early biomarker for AD. It should be noted that a lot of human studies discussed here were based on a low sample size at higher risk for false positives due to random variations in a small number of data points. Thus replications are needed to validate the findings. Nevertheless, disruptions in slow oscillations might underlie the memory impairments as part of AD progression, since SWA plays a key role in declarative memory consolidation during sleep. Moreover, animal models of AD recapitulate the slow wave disruptions and can be used for mechanistic studies. Use of leading-edge technologies, including optogenetics, wide-field imaging and multiphoton microscopy, in addition to traditional technologies, including electrophysiology, provided insight into the mechanisms of slow wave disruptions in AD. A better understanding of the relationship between SWA disruptions and memory decline may shed light on the mechanistic pathways underlying AD-associated memory impairment. SWA restoration provides a promising novel therapeutic target for AD. Utilizing noninvasive brain stimulation technologies and medications that upregulate inhibitory elements of cortico-thalamic circuits may prove to become efficient therapeutic strategies. Development of novel therapeutic interventions targeting SWA during NREM sleep early in the disease progression might slow memory decline in the elderly and delay AD onset in MCI or healthy individuals at risk for developing AD.
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